BeiGene, Ltd. American Depositary Shares - BGNE STOCK NEWS

BeiGene announced it will present new data from its hematology portfolio at the European Hematology Association 2024 Hybrid Congress (EHA2024) in Madrid, Spain, June 13-16, 2024.

Highlights include 28 abstracts, with four oral presentations. Key studies focus on BRUKINSA® (zanubrutinib), sonrotoclax, and BGB-16673. BRUKINSA, in combination with venetoclax, showed strong efficacy and favorable safety in high-risk CLL/SLL patients.

Sonrotoclax demonstrated promising safety and efficacy as a monotherapy and in combination therapies, particularly with BRUKINSA. Also, BGB-16673, a BTK degrader, showed encouraging results in BTK inhibitor-resistant diseases.

These findings underscore BeiGene's commitment to advancing treatment options for B-cell malignancies and other hematological conditions.

BeiGene reported total revenues of $752 million in the first quarter of 2024, with product revenue reaching $747 million, an 82% increase from the prior-year period. BRUKINSA revenue was $489 million, showcasing growth in the U.S. and Europe. The company is focusing on advancing its late-stage hematology pipeline, improving operating leverage, and aiming for sustainable profitability. Key updates include the FDA approval for BRUKINSA in follicular lymphoma and the sales growth of TEVIMBRA in various indications. The company also highlighted progress in its hematology and solid tumor programs, along with key pipeline advancements in lung, breast, and gastrointestinal cancers.

BeiGene, a global oncology company, released its 2023 Responsible Business & Sustainability Report, highlighting achievements, expansion plans, and commitment to innovation. Key points include treating over 1 million patients with BTK inhibitor BRUKINSA and anti-PD-1 antibody TEVIMBRA, opening a new facility in the U.S., and setting quantitative climate goals. The report focuses on advancing global health, empowering colleagues, innovating sustainably, and operating responsibly.

BeiGene, a global oncology innovator, is set to present new data at the 2024 ASCO Annual Meeting showcasing the efficacy and safety of BRUKINSA and TEVIMBRA across various B-cell malignancies and solid tumors. The company will highlight BRUKINSA's differentiated clinical profile and present data comparing its efficacy with other treatments in chronic lymphocytic leukemia. TEVIMBRA will be featured in multiple presentations, demonstrating its potential across different tumor types. The company's solid tumor development program will be a focal point at the meeting, with new data from the RATIONALE-306 study on TEVIMBRA's efficacy in esophageal squamous cell carcinoma. BeiGene's commitment to addressing unmet patient needs through innovative treatments is evident in the research outcomes they will share at ASCO.

BeiGene receives European Commission approval for tislelizumab as a treatment for non-small cell lung cancer, marking the second approval in the region. The comprehensive development program included three Phase 3 clinical trials demonstrating the benefits of tislelizumab for both treatment-naïve and relapsed NSCLC patients.

BeiGene's TEVIMBRA receives FDA approval for treating adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy, showing significant survival benefits in Phase 3 RATIONALE 302 trial.

Pi Health, a subsidiary of BeiGene, Ltd. (NASDAQ: BGNE), secures over $30M in Series A funding to revolutionize global access to clinical trials and innovative medicines. The funding round, led by AlleyCorp and Obvious Ventures, aims to address the inefficiencies in the clinical trial process by leveraging cutting-edge technology. Pi Health's FICS software streamlines data collection and accelerates drug development, potentially saving lives and reducing costs. The company's mission is to democratize cancer care and research by increasing patient enrollment and enhancing global access to life-saving treatments.

Armenia and Nepal are the first countries to receive BRUKINSA, a treatment for chronic lymphocytic leukemia, as part of a collaboration between Max Foundation, BeiGene, and BeiGene Foundation. The initiative aims to provide access to the medicine in 29 low- and middle-income countries.

BeiGene's BRUKINSA receives accelerated approval from the FDA for the treatment of relapsed or refractory follicular lymphoma in combination with obinutuzumab, marking its fifth indication in B-cell malignancies. The approval is based on positive results from the ROSEWOOD trial, showcasing higher overall response rates. BRUKINSA is the first and only BTK inhibitor to show efficacy in this type of malignancy, with a broad label covering five oncology indications globally.